AGP Executive Report

Last update: 6 hours ago

Health Access in Gabon: In Makokou (Ogooué-Ivindo), President Brice Oligui Nguema officially opened a new CNSS agency and launched modernized La Poste services, aiming to cut the distance and cost barriers that keep retirees, workers, and families from completing social protection procedures. Sickle Cell Care in West Africa: A Senegalese company, Teranga Pharma, says it has started producing the first Africa-made generic hydroxyurea, a WHO-recommended treatment that can reduce painful crises, hospital stays, transfusions, and premature death—bringing hope to families facing high import costs. TB Vaccine Update: A phase 3 trial in sub-Saharan Africa found a new TB vaccine candidate (VPM1002) did not meet the standard set by BCG for preventing TB infection in newborns, underscoring the need for better, scalable options. Arms & Public Health Link: At the UN arms trade treaty conference in Geneva, Gabon’s diplomat urged African states to sign, ratify, and domesticate the treaty to curb illicit small arms and light weapons—an indirect but important factor for safer health systems.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

No AGP Wire articles available right now.


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate

fallback image
Aug. 25, 2026

University of Miami's Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open Science

GlobeNewswire, Inc.

fallback image
Jun. 5, 2026

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

GlobeNewswire, Inc.

fallback image
Feb. 3, 2026

Gelatine Sculpt (2026 CONSUMER REPORT): Liquid Metabolism Formula Gains Attention as "Bariatric Jelly" Alternative for Healthy Weight Management

GlobeNewswire, Inc.

fallback image
Jul. 30, 2026

Sugar Reset Drops Label Guide: What the Supplement Facts Panel, Serving Directions, and Safety Statements Disclose for 2026

GlobeNewswire, Inc.

fallback image
Aug. 20, 2026

Half-Year Results 2026: Boskalis delivers solid performance amid challenging market conditions

GlobeNewswire, Inc.

fallback image
Jul. 7, 2026

MAPS Publishes Ibogaine Investigator's Brochure as a Free, Open-Access Resource

GlobeNewswire, Inc.

More press releases

Video Stories

YouTube video thumbnail: Guardians of Gabon’s Green Heart: Nature, Tradition, and Spirit
Play
Guardians of Gabon’s Green Heart: Nature, Tradition, and Spirit
YouTube video thumbnail: Wildlife Viruses in Gabon: The Hidden Risks of Bushmeat Consumption
Play
Wildlife Viruses in Gabon: The Hidden Risks of Bushmeat Consumption
Affinity Group Publishing Logo Showcase
Discover Affinity Group Publishing
YouTube video thumbnail: Guardians of Gabon: The Fight to Preserve Africa's Lush Rainforests and Forest Spirits
Play
Guardians of Gabon: The Fight to Preserve Africa's Lush Rainforests and Forest Spirits
YouTube video thumbnail: The Dictator Who Ruled Gabon for 42 Years
Play
The Dictator Who Ruled Gabon for 42 Years

Video Title

Sign up for:

Health News Daily Gabon

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health News Daily Gabon

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.